Recent developments with Dyne Therapeutics Inc (DYN) have led to the company’s beta value being reach 0.88 cents.

Dyne Therapeutics Inc (NASDAQ: DYN) kicked off on Friday, up 24.01% from the previous trading day, before settling in for the closing price of $34.50. Over the past 52 weeks, DYN has traded in a range of $6.40-$25.50.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

While this was happening, its average annual earnings per share was recorded -16.64%. With a float of $29.72 million, this company’s outstanding shares have now reached $55.64 million.

Dyne Therapeutics Inc (DYN) Insider and Institutional Ownership

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Dyne Therapeutics Inc is 51.59%, while institutional ownership is 65.37%. The most recent insider transaction that took place on Jan 26, was worth 490,510. In this transaction Chief Business Officer of this company sold 20,000 shares at a rate of $24.53, taking the stock ownership to the 143,618 shares. Before that another transaction happened on Jan 26, when Company’s SVP, Head of Finance & Admin. sold 13,000 for $24.34, making the entire transaction worth $316,420. This insider now owns 124,228 shares in total.

Dyne Therapeutics Inc (DYN) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of 270.14 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -16.64% per share during the next fiscal year.

Dyne Therapeutics Inc (NASDAQ: DYN) Trading Performance Indicators

Take a look at Dyne Therapeutics Inc’s (DYN) current performance indicators. Last quarter, stock had a quick ratio of 5.67.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.59, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -3.06 in one year’s time.

Technical Analysis of Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (NASDAQ: DYN) saw its 5-day average volume 0.74 million, a negative change from its year-to-date volume of 3.09 million. As of the previous 9 days, the stock’s Stochastic %D was 75.43%. Additionally, its Average True Range was 1.66.

During the past 100 days, Dyne Therapeutics Inc’s (DYN) raw stochastic average was set at 92.20%, which indicates a significant increase from 83.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.36% in the past 14 days, which was lower than the 99.75% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $15.75, while its 200-day Moving Average is $11.97. Nevertheless, the first resistance level for the watch stands at $25.01 in the near term. At $26.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $27.09. If the price goes on to break the first support level at $22.93, it is likely to go to the next support level at $21.84. The third support level lies at $20.85 if the price breaches the second support level.

Dyne Therapeutics Inc (NASDAQ: DYN) Key Stats

The company with the Market Capitalisation of 1.47 billion has total of 61,384K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -168,100 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -60,210 K.